You can discuss with your Klinic provider which option is most suitable for your specific situation
Two leading GLP-1 receptor agonists dominate the weight loss conversation: semaglutide and tirzepatide
The nutrition and lifestyle skills described above are especially important if the person plans to stop using the GLP-1
[11] [20] Patients should not adjust doses independently but may discuss timing strategies with their healthcare provider
Japan stays aligned with the global rate because treatment eligibility keeps platform value tied to clinical oversight
Le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DC, Van Gaal L, Ortiz RV, Wilding JP, Skjth TV, Manning LS